Abstract
The treatment of metastatic breast cancer continues to evolve with better understanding of the underlying biology and genetics and newer medications. Although not yet curable, progress is being made with increases in overall median survival. Several new medications are changing the treatment paradigm for advanced disease.
| Original language | English |
|---|---|
| Pages (from-to) | 27-32 |
| Number of pages | 6 |
| Journal | Journal of Managed Care Medicine |
| Volume | 16 |
| Issue number | 3 |
| State | Published - Sep 16 2013 |
Keywords
- A do-trastuzumab emtansine is a new option for HER -2 positive disease
- E verolimus is a new option in the postmenopausal, estrogen receptor positive patients
- I n premenopausal and postmenopausal patients with estrogen receptor positive disease, sequential endocrine agents are used until no longer effective
- Metastatic breast cancer is not curable
- Treatment is chosen based on tumor biology